This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,748 to support research aimed at evaluating the therapeutic and preventive potential of anti-fibrotic drugs for Idiopathic Pulmonary Fibrosis (IPF). The key objectives are to: 1) Integrate micro- and macro-scale lung tissue stiffness measurements with traditional IPF drug discovery endpoints, and 2) Demonstrate proof-of-concept in testing the therapeutic and preventive capabilities of IPF drugs, such as nintedanib and epigallocatechin gallate, using human precision-cut lung slices. This research will develop a stiffness-based drug discovery platform for IPF, with potential to better understand and fine-tune promising drug candidates in a future Phase II project.
Generated 3/25/25, 5:28 AM